{"name":"Anagram Therapeutics, Inc.","slug":"anagram-therapeutics-inc","ticker":"","exchange":"","domain":"anagram.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ANG003 Dose A","genericName":"ANG003 Dose A","slug":"ang003-dose-a","indication":"Investigational treatment for COVID-19","status":"phase_2"},{"name":"ANG003 Dose B","genericName":"ANG003 Dose B","slug":"ang003-dose-b","indication":"Investigational treatment for COVID-19","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ANG003","genericName":"ANG003","slug":"ang003","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ANG003 Dose A","genericName":"ANG003 Dose A","slug":"ang003-dose-a","phase":"phase_2","mechanism":"ANG003 Dose A is an investigational RNA-targeting therapy.","indications":["Investigational treatment for COVID-19"],"catalyst":""},{"name":"ANG003","genericName":"ANG003","slug":"ang003","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANG003 Dose B","genericName":"ANG003 Dose B","slug":"ang003-dose-b","phase":"phase_2","mechanism":"ANG003 Dose B is an investigational RNA-targeting therapy.","indications":["Investigational treatment for COVID-19"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOSHZvUVJyM3NmZ0g2dEFjTEgyZ2NiX1ZMZU5ETDhNcmxvczh6UDJCclk5WjUyZFJ2SzVxV2lJZ2FFSlcyc2otdTBRaGFPZVFfeU11Z3pqMjJIektfQ2hiTDVJRTRDVXUwMktxU204SjlJcUdsQ0tJOTFWUllwTmVHc0ZKbUR6aVNtWkxBQXY1NXpUbmwtUkswam5oV0Z0VUlfTlVPa09QdUNuVUs3OFozTjczV2Fnbmt3MjJ2Q3RsRjAweGFXRmNmNUhlSnNSWlRhZExfeENDblR4U2Z1akREU3pQRWd1TDY0bWJFRTQwcm9UZDRLVGhlOUZ5N1FGVjNlazRsellIbmFnY2N4anQyY3JsLUhkRmFKaTdaeDdvNlBSTzNIbWxhRmEtN2E3bml3cDhIRHZUZThSd2tuVEpBZGNkWGZJRXh1Y054NlVqTQ?oc=5","date":"2026-04-08","type":"earnings","source":"Barchart.com","summary":"Exocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories - B","headline":"Exocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQQzJWN1A4NGozZDZQMVlMa1MzbGpHTjJIUWJ6MFRvckdWd2RWaU1VbDY5a09tc1QxNzJaZW9NQnN2LUliaTRBQTRJRFhhazBSYlk1Y09UY3JiLW9zZHZBb0RVZEtPODZZUGdVQl9vRzZtYURKbTVzaGZWTGRMbUtuUk96NFlQdG1SamtuUHFjRHNjQUYwWWhMSFVQWEU2MlZDckVNZDNETktxcFRCa1lQT3ZHdXJSM2YyRnBRZEhWUWdxMlk4MFp2MHFxMHg5dTRIUGFNQ1VDd2JkMDduWGRYSUFDSGRpMDdBbVJOeTdR?oc=5","date":"2025-10-30","type":"pipeline","source":"GlobeNewswire","summary":"Epicured Appoints Industry Veteran Patricia Bradley to Oversee Life Sciences Business - GlobeNewswire","headline":"Epicured Appoints Industry Veteran Patricia Bradley to Oversee Life Sciences Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2hMczZSNm9ka1BJdWgtbEQxSlh4MS1oNUt1Z0tvdEVWT0FMalk4Y25OQjJEb1hKUFRuUHRZblB1ZzdJSUMtZHhZMTBQTVVtNS1uSzdyUVh3SU4zOS1JMEZfcnFVTm5oY1c2WGRfaXdYSGZXRTgtdmRieWhtMWlOeFNMOFN3WFFyUGNQLUhEcXh4a0JtZVlKLTFoVUxtNjVubmRZVkEwcnh3MHVyM0d4Z3lBRER3Yy1tZGIzaFdkbGV1VE5MS0Z1NmhFNW8xSWNnUzdSekUwUjdfWkZMTUc3UkxOVWlhaktYeFVkVFlsemJqeDFUbU05c0hzLTRTODN1dzdQanpRSmpSazNOZHdWMzZB?oc=5","date":"2025-08-25","type":"pipeline","source":"GlobeNewswire","summary":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - GlobeNewswire","headline":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxON2tDOFZQNk92ZkgzSlpUU2dYNWF0SUQxdDdsbmotTTFEVUVVSHZLc2VxREw3RG9pWXZsckRteV91NHZRd3A3aUdPZEl4ZldOOEhZMzdqeFpacERrLVpTRHc3WlZVZDl5RHhJNUVneHhNQWZ4QzJJOWp6RG13b1pjNlJYbjAyZnpNa0Z0LWZhZVNxWlJJbjVDTVN4cHpwcFc2cWM1dmtPd1hmMUxvckJBYllCSnNHeTlCekYwTE92RDlqRVFKWDRpSF92THQ0aFEwaXlzUlpROVQzaUtZc1VMSS1XUldsVkFtd25DaUc1UkF5NVAyNmwwQ29Wbzc4TWFwRWU4b2ZB?oc=5","date":"2025-02-06","type":"pipeline","source":"PR Newswire","summary":"Global Airway Clearance Devices for Cystic Fibrosis Market to Show Positive Growth at a CAGR of ~5% by 2032 | DelveInsight - PR Newswire","headline":"Global Airway Clearance Devices for Cystic Fibrosis Market to Show Positive Growth at a CAGR of ~5% by 2032 | DelveInsig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNSHpaX3phMTctcFVxTEU4RUVtZ1d1MWJuX0t5NWJJTzRmTE9Bd21tQ2VJbjRYbU5DQVZvMmV5X0xROTBrbDRiNUtWNDE5N25wRDJBSWc1U3VydzdwQWJDM3JpV1VEVkdIaHYtRS1FcWUwbXlHX0txa1pwNFZ2bHlkQm54TVpzMENyMDBFUDVTaXFUYXc0eGZZX0FFcXJGdGtPeTI0QWpsTVNuNW9QeG16WU9xblBwRk1obEdQRTBfblFLTmNDS3NabVlVX1hCc3VxWHc4LXFhSzJQVDluMnNzdUpHYTdWQzRtSjdaUDlpX2NBYzhtaFI5ZlFjUU1peFFVZzNsTzJidkdTcldpUGlQd0ZjUnIzSmVHM0o4aENicnU?oc=5","date":"2025-01-28","type":"trial","source":"PR Newswire","summary":"Anagram Therapeutics Selects Epicured as Nutrition Partner On Successful Cystic Fibrosis and Exocrine Pancreatic Insufficiency Dosing Study - PR Newswire","headline":"Anagram Therapeutics Selects Epicured as Nutrition Partner On Successful Cystic Fibrosis and Exocrine Pancreatic Insuffi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVEJwUGRkeHZzLVdhaV9RRmdGbThzM0hHc0RTOTR0dzdtZUZYb1hQckhxMDNGRDVMem1rOVBkRm5ldERIN0xSY18xMXc1MGtOWW9QQVZrWDBBZ24xblFjRjhlaTg5MTVPU3hEUmNBNUJUZUFLTloyTGdvTkFpX1FiM0l2ajQ4U05zamtUZWpZSHhjaXRUeDFTVExtMUVTV1FsVno3TmFCREdLb0JiOU1IV3gxLTRrNmlNYnZtWmxNcDkzT1ZvMG9xd01zYWNNTGpGeUJEb2txcU9XR3JNNFZweGRyUUUwYTFIeFd3?oc=5","date":"2024-11-14","type":"pipeline","source":"GlobeNewswire","summary":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxQbHVQVGNLNTFfUHhJR0dZZUxacTk5eVI1TnpHX0p1cnVCOVJzWGVweWs1MDFaNXk1dUZpTXlHNGV1emppS3RXa3llSno2eTlxTUhITDYyQkV3dEtQallScldQZ25aNm9BN1ctc25zeWpSMG5ITE5MenY1U0E2Z1BqWGdTZVF5SFZCYkZIQzRUQVctZkt4cGtRTGF6U1BCbE1ra0pjZ2tFQ2JtTEtDdkpQVVdQNW8yY2xadmVrazBydmtWdFBHaUFrWXVNWDVlMXV0YkNQbGlJdFVLRWI0Sk1haHhlelB5dkNCRkFWRmdlZE9RNEtzMzBCUXhFank5TG92R3hnT3ZkU0pYeUk3S0V1a3RvVDRJNmR1YnE5X2p0b181V3ljNkFJamdlV3FjX1I5X1JyT0pxU2c?oc=5","date":"2024-11-13","type":"pipeline","source":"GlobeNewswire","summary":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over - GlobeNewswire","headline":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPWlpFTEV0d2xDQXJxN1ZSVnVwT0ZzYkpVb2NBc0h1dVZZQ1ZqRnBPRmhCdEY2Ym9WOGdQYmJUclRaVU1Vc2VYcmpQa1N1Q3FSS3BEdVVaNU5NWjJGQ3BHdzJsZ3BqYzdIamV5X0R1Y3RycS1uelN3UTB4UjdSZ1Y1eWJSYVNSNG1Zd2RBb05TaE9fZlBSQWdNZktROGUzbDVSUG9JbURnSl9EdmlLU2FEUXRLY3ByQVNjZFBkd3hPREFEaC1wY3JYTjFYZFU0X2tJUDE5TC1FWFdUT0NZQW5qYnItQnF4Sm8tLVhiZnFR?oc=5","date":"2024-10-08","type":"deal","source":"Business Wire","summary":"Avania Buys Spanish MedTech CRO Anagram to Enhance Its Core CRO Offering in a New European Geography - Business Wire","headline":"Avania Buys Spanish MedTech CRO Anagram to Enhance Its Core CRO Offering in a New European Geography","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxNZmt4UmJ3WDJDc3NIeVF5a0tySHpfdGRNR3JsS3ozYUZvRDN5Sk5PcmszNE9tSmYzbTUxaE5zZG1CbWFub2JocF8yZmY5UXhCSHd2dGczSXNabTNpMHpvU0YxZDRMcnNfRjVnajZUZ1RHUlJ6ckUySzBXZ3lqeUlia3RPdWVtTEhuZU52YkZkdGpPajlBN3VfVFMwelZ4MXh6eHpqSFVBR2NlYlBNRUZDT0xUdV9sYWJkU3RmZXFNVzZaSHFNaW85eW1KUWtwWTdHNkdUUVc1MG5XUG85b0tMTTRCcl9PVzNfSTlsSEJJa1JqNERzazE1T1VlMmhnR2twVkFHSm15R2xsUmwtV29pSmZBRFJaMjRacWhqSEZqNjR6Q24xaVBwcHlGUDJOc1hFRGxMZWZRYVRRUzRtRUE?oc=5","date":"2023-10-04","type":"deal","source":"Business Wire","summary":"ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders - Business Wire","headline":"ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQeVB1Z3k5VWVnNVlBcm9LZ2NTWDlCZFRBMjQ4MVp0ZnhjMjdiYWZaeWVhZUpCdVpoZExoYXcxWGVCWEpzTjRYc3V0ZXBoZWtuNHBIeDJIWnM4SDU0SGNKeUZSM1lwLVFlSkFHWjA1X1dTQ1ZsY3pmSDFPTV9FUjdGNXlQN2N5emhzcXMxT3NDb29JZ1RvWUU3bXJHV1ZySVRpd0NTVXpVeXBZMlNqU3V6YzVlZGtmQWxKcUE?oc=5","date":"2023-04-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Anagram wins $15.5m boost to develop enzyme therapy for cystic fibrosis - Pharmaceutical Technology","headline":"Anagram wins $15.5m boost to develop enzyme therapy for cystic fibrosis","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}